Virtual San Antonio Breast Cancer Symposium
December 8-11, 2020

The majority of HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test

RxPONDER Clinical Trial Key Findings

  • The majority of HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test
  • Postmenopausal women with 1-3 positive nodes and Recurrence Score result 0-25 can forgo adjuvant chemotherapy regardless of clinical pathological parameters
  • Premenopausal women with 1- 3 positive nodes and Recurrence Score result 0-25 significantly benefit from chemotherapy
  • RxPONDER study results are expected to be practice-changing for N1 HR+, HER2-, early breast cancer patients

RxPONDER Clinical Trial Design

RxPONDER graphic
  • RxPONDER, independently led by the SWOG Cancer Research Network, is one of the largest clinical trials for patients with HR+, HER2- early breast cancer and N1 disease
  • The trial was designed to determine the effect of chemotherapy, if any, in patients who had a Recurrence Score result 0-25

RxPONDER Study Results demonstrate that the Oncotype DX® test can now spare chemotherapy use in the majority of women with node-positive early-stage breast cancer

Product Industry Theatre Video

Enhancing the Utility of the Oncotype DX Breast Recurrence Score Test

Speaker Dr. Christy Russell, Senior Director of Medical Affairs at Exact Sciences, reviews data that were presented at SABCS 2020: RxPONDER, ADAPT and RSClinTM Education Tool


Yes or No? Answering CT and ET Questions Through a Case-based Discussion with the Oncotype DX Test

Speakers Jeremy Force, DO, Alison Stopeck, MD and Christy Russell, MD


Presentations of Interest

An analysis of the clinical and economic impact of the 21-gene Recurrence Score in invasive lobular early-stage breast cancer in Ireland
PS4-23 | Tharmabala / Walshe

A prospective multicenter study evaluating the impact of the 21-gene Breast Recurrence Score upon physician treatment decision and cost in N+ breast cancer patients in Quebec
PS4-27 | Hassan / Robidoux

The feasibility of obtaining Oncotype DX Breast Recurrence Score results from the metastatic sites of patients with HR+ metastatic breast cancer
PS5-37 | Gemmill / Stopeck

General Session 3 | 8:45 AM CT
SWOG S1007: adjuvant trial randomized ER+ patients who had a Recurrence Score <25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy

Can genomic profiling eliminate the need for SLNB in ER+, T1-2 breast cancer
PD4-03 | Jackson

Neoadjuvant nab-paciltaxel weekly vs dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC: results from the neoadjuvant part of ADAPT HR+/HER2- trial
GS4-03 | Kuemmel

Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Frist efficacy results from the ADAPT HR+/HER2- trial
GS4-04 | Harbeck

ADAPTlate: A randomized, controlled, open-label, phase-III trial on adjuvant dynamic marker-adjusted personalized therapy comparing abemaciclib combined with standard adjuvant ER versus standard adjuvant ER in (clinical or genomic) high risk, HR+/HER2- early breast cancer
OT-01-02 | Gluz

Development and validation of a tool integrating the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer
GS4-10 | View full publication | Sparano

Introducing the RSClin™ educational tool: for your patients with HR+, HER2–, early-stage, node-negative invasive breast cancer


The RSClin educational tool provides enhanced clarity when more nuanced information is needed for treatment decisions.

RSClin™ Updates

Sign up for more information about the new RSClin Educational Tool.

I agree to be contacted at the email provided above for marketing purposes and accept the Terms & Conditions. For more information about our privacy practices, please read our Privacy Policy.*
Making cancer care smarter.™